From venture capital to building industries: How biotech ecosystems scale

Venture capital plays an essential role in the early life of biotechnology ecosystems. It funds scientific discovery, supports founders willing to pursue difficult ideas and absorbs the uncertainty that accompanies early-stage innovation.

But venture capital alone does not build an industry.

The long-term success of biotechnology ecosystems depends on what happens after the venture phase. The true test is whether early investment activity evolves into a sustainable industrial sector capable of producing therapies, manufacturing advanced biologics and supporting long-term economic value.

The transition from venture-backed experimentation to industrial stability is where many emerging biotech ecosystems struggle.

Venture capital is designed to fund risk. Sustainable industries are built to manage it.

In the early stages of a biotech ecosystem, venture capital acts as a catalyst. It supports scientific founders, finances early research and creates the first generation of companies capable of transforming laboratory discoveries into investable programs. Without this risk-tolerant capital, few innovations would reach the clinical development stage.

However, once companies reach a certain level of maturity, the ecosystem must evolve.

Biotech companies cannot remain permanently in a venture-backed state. Clinical development, regulatory approval and global commercialization require scale, infrastructure and operational discipline that extend far beyond the startup model. 

Venture capital is designed to fund risk. Sustainable industries are built to manage it

Manufacturing facilities must be built. Regulatory teams must grow. Clinical trials must be managed across multiple geographies. Supply chains must be secured. Talent pipelines must expand.

These are not startup activities. They are industrial ones.

This is where venture capital must shift its role.

Experienced biotech investors understand that their responsibility is not only to fund companies but also to help transition them toward institutional stability. Venture capital firms often facilitate strategic partnerships, support mergers and acquisitions, and encourage consolidation of complementary technologies into stronger platforms.

Mergers and acquisitions play a particularly important role in this transition.

Biotech ecosystems that rely exclusively on independent startups often struggle to achieve scale. Smaller companies may possess valuable scientific breakthroughs but lack the infrastructure required for commercialization. Strategic acquisitions allow these assets to be integrated into larger organizations with the operational capacity to bring therapies to market.

In mature markets such as the US and Europe, mergers and acquisitions are a normal and healthy feature of biotech development. They allow early innovation to be absorbed into companies capable of manufacturing, regulatory navigation and global distribution.

For emerging biotech ecosystems, this progression is essential. Venture capital should not aim to perpetuate endless startup creation. Its purpose is to generate the first generation of companies that can eventually evolve into industrial leaders.

Saudi Arabia’s biotechnology ambitions make this transition particularly important.

The Kingdom has already demonstrated a commitment to developing the life sciences sector through national strategy, regulatory reform and targeted investment. Venture capital will continue to play a crucial role in supporting early-stage discovery and encouraging scientific entrepreneurship.

But the long-term objective must be larger than the startup phase.

Saudi Arabia has the opportunity to build biotech companies that grow into regional and global industrial players — companies capable of developing multiple therapeutic pipelines, operating advanced manufacturing facilities and contributing to global healthcare innovation.

Achieving this requires capital structures that support long timelines, governance frameworks that encourage consolidation when appropriate, and investors willing to prioritize durability over speed.

Venture capital is the beginning of the story.

Industrial capability is the outcome.

When venture-backed innovation evolves into companies that manufacture, export and scale science into economic value, the ecosystem has succeeded.

The real measure of a biotechnology ecosystem is not how many startups it creates, but how many enduring companies it produces.

And the transition from venture capital to sustainable industry is where that outcome is determined.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.